Jumbo S.A. engages in the retail sale of toys, infant supplies, seasonal items, home products, decoration items, books, and stationery in Greece, Cyprus, Bulgaria, and Romania. The company also operates e-jumbo, an onlin…
Industry Peers
Specialty Retail| Headline | Source | Time |
|---|---|---|
Older | ||
NNewsIT | ||
ΜΜακεδονικό πρακτορείο ειδήσεων | ||
PPhilenews | ||
ΟΟικονομικός Ταχυδρόμος | ||
ΗΗμερησία | ||
FForbes Greece | ||
DDnews | ||
BBusinessDaily | ||
 Heineken’s Strongbow adds NaviLens levels to packaging The cider brand has added a high-contrast NaviLens QR code to its cans. | ||
 3 firms to lay off hundreds of North Jersey-based employees BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty | ||
 Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
 Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||